醫(yī)療特長(zhǎng)：從事消化內(nèi)科臨床工作近30年,，對(duì)炎癥性腸?。肆_恩病、潰瘍性結(jié)腸炎）,、罕見(jiàn)?。ㄟz傳性血管性水腫、IgG4相關(guān)性疾病,、家族性地中海熱、糖原累積病等）及自身免疫性腸病,、乳糜瀉,、PD-1相關(guān)免疫性腸炎、蛋白丟失性腸病,、P-J綜合征（黑斑息肉?。┑刃∧c疑難疾病的診斷治療有較豐富的經(jīng)驗(yàn)，擅長(zhǎng)小腸鏡,、膠囊內(nèi)鏡及超聲內(nèi)鏡,，主要研究方向?yàn)檠装Y性腸病、罕見(jiàn)病及小腸疾病,。
研究方向：
炎癥性腸?。肆_恩病,、潰瘍性結(jié)腸炎）、罕見(jiàn)病,、小腸疾病,、小腸鏡診治技術(shù)
主要教育和工作經(jīng)歷：
1994年畢業(yè)于中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系，畢業(yè)后一直在中山大學(xué)附屬第一醫(yī)院消化內(nèi)科工作,，2005-2006年到香港威爾斯親王醫(yī)院進(jìn)修,，2007年獲中山大學(xué)內(nèi)科學(xué)博士學(xué)位。
社會(huì)兼職：
1.中華醫(yī)學(xué)會(huì)消化病學(xué)分會(huì)炎癥性腸病學(xué)組心理協(xié)作組委員,；2.中華醫(yī)學(xué)會(huì)消化內(nèi)鏡學(xué)分會(huì)膠囊內(nèi)鏡協(xié)作組委員,；3.廣東省醫(yī)學(xué)會(huì)消化病學(xué)分會(huì)炎癥性腸病學(xué)組副組長(zhǎng)；4.廣東省醫(yī)師學(xué)會(huì)消化內(nèi)鏡學(xué)醫(yī)師分會(huì)小腸內(nèi)鏡專業(yè)組副組長(zhǎng),；5.廣東省醫(yī)師協(xié)會(huì)消化科醫(yī)師學(xué)分會(huì)委員,；6.中華炎性腸病雜志青年學(xué)術(shù)組副組長(zhǎng)
論著：
1.Zhang SH, Chen BL(共同第一作者),Wang BM,Chen H,Li Y，Cao Q,Chen MH.Effect of induction therapy with Olamkicept vs placebo on clinical response in patient with active ulcerative colitis.JAMA.2023.329(9):1-10
2.Chen BL,Zhong J,LiXL,Pan F,Ding TJ,Zhang Y,Chen H,Liu F,ZhangZY, Zhang L,Rafal Drozda,Oleksandr Oliinyk Aik Han Goh Chen X Sun X; David T Rubin, William J Sandborn,Chen MH; Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study, Gastroenterology, 2022
3.Zhuang XJ,Chen BL(共同第一作者), Huang SS,Han J,Zhou GS,Xu S,Chen MH,Zeng ZR,Zhang SH. Hypermethylation of miR-145 promoter-mediated SOX9-CLDN8 pathway regulates intestinal mucosal barrier in Crohn's disease,EBioMedicine, 2022, 76
4.Chen BL,Gao X,Zhong J,Ren JL,Zhu X, Liu ZJ,Wu KC,Jasmina Kalabic,Yu ZQ,Bidan Huang,Nisha Kwatra,Thao Doan,Anne M. Robinson,Chen HM. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial, Therap Adv Gastroenterol, 2020, 13.
5.Feng T,Chen BL(共同第一作者),Bella Ungar et al. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn’s Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis 2019.25 (11):1813-1821
6.Feng T,Chen B(共同第一作者),Li L, Huang S, Ben-Horin S, Qiu Y, Feng R, Li M, Mao R, He Y, Zeng Z, Zhang S , Chen M. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. Inflamm Bowel Dis, 2017, 23 (10): 1817-1824.
7.Qiu Y,Chen BL(共同第一作者), Mao R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Chen MH .Systematic Review with Meta-Analysis: Loss of Response and Requirement of anti-TNFalpha Dose Intensification in Crohn's Disease. J Gastroenterol, 2017, 52 (5): 535-554.
專著：
克羅恩病--基礎(chǔ)研究與臨床實(shí)踐
潰瘍性結(jié)腸炎--基礎(chǔ)研究與臨床實(shí)踐
其他主要工作成績(jī)（比如獲獎(jiǎng)情況）：無(wú)
